Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
— Abstracts Report on Screening Population for PALISADE Phase 3 Clinical Trial and Current Management of Peanut Allergy — BRISBANE, California --(BUSINESS WIRE)--Jun. 15, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food
Toggle Summary Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— Final Study Visits Projected Around Year-End 2017; Topline Data Expected in the First Quarter of 2018 — — More Than 97 Percent of Patients Currently On Study Are Through the Up-Dosing Phase — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 12, 2017-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the Goldman Sachs 38 th Annual Global
Toggle Summary Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy
— Florida Plant Can Produce AR101 for Peanut Allergy for Global Market — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 7, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today hosted a ribbon-cutting ceremony to
Toggle Summary Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
— “Real-World” Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif. --(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007)
Toggle Summary Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
BRISBANE, Calif. --(BUSINESS WIRE)--May 9, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly , M.B.B.S.,
Toggle Summary Aimmune Therapeutics Announces First Quarter 2017 Financial Results
BRISBANE, Calif. --(BUSINESS WIRE)--May 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced financial results for first quarter
Toggle Summary Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
— New CFO Is an Established Leader and Healthcare Industry Veteran — BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 13, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the appointment of Eric Bjerkholt as Chief Financial Officer. Mr. Bjerkholt joins Aimmune from Sunesis Pharmaceuticals,
Toggle Summary Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
— Company Began 2017 with Approximately $283 Million in Cash and Investments, Sufficient to Support Current Development Plans through Regulatory Submissions — — Conference Call and Webcast Today at 8:00 a.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 15, 2017-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
- Conference Call and Webcast to Follow at 8:00 a.m. ET / 5:00 a.m. PT - BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its financial results for